Grandeur Peak Global Advisors LLC Has $251,000 Position in Zoetis Inc. (NYSE:ZTS)

Grandeur Peak Global Advisors LLC cut its position in Zoetis Inc. (NYSE:ZTS) by 13.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,591 shares of the company’s stock after selling 250 shares during the quarter. Grandeur Peak Global Advisors LLC’s holdings in Zoetis were worth $251,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. FIL Ltd increased its position in Zoetis by 71.4% during the 4th quarter. FIL Ltd now owns 339,900 shares of the company’s stock worth $56,254,000 after purchasing an additional 141,631 shares in the last quarter. Sittner & Nelson LLC acquired a new position in Zoetis during the 4th quarter worth approximately $51,000. ExodusPoint Capital Management LP increased its position in Zoetis by 17.9% during the 4th quarter. ExodusPoint Capital Management LP now owns 6,169 shares of the company’s stock worth $1,021,000 after purchasing an additional 937 shares in the last quarter. Engineers Gate Manager LP increased its position in Zoetis by 151.1% during the 4th quarter. Engineers Gate Manager LP now owns 8,111 shares of the company’s stock worth $1,342,000 after purchasing an additional 4,881 shares in the last quarter. Finally, Schroder Investment Management Group increased its position in Zoetis by 9.5% during the 4th quarter. Schroder Investment Management Group now owns 423,633 shares of the company’s stock worth $70,111,000 after purchasing an additional 36,659 shares in the last quarter. Institutional investors own 90.03% of the company’s stock.

In related news, EVP Roxanne Lagano sold 6,000 shares of the stock in a transaction on Wednesday, May 19th. The shares were sold at an average price of $169.05, for a total transaction of $1,014,300.00. Following the transaction, the executive vice president now directly owns 53,642 shares of the company’s stock, valued at $9,068,180.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.17% of the stock is owned by corporate insiders.

ZTS has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $186.00 price objective for the company in a research report on Tuesday, June 1st. Argus upped their price target on shares of Zoetis from $185.00 to $195.00 and gave the company a “buy” rating in a research report on Friday, May 28th. Barclays upped their price target on shares of Zoetis from $200.00 to $208.00 and gave the company an “overweight” rating in a research report on Friday, May 7th. upped their price target on shares of Zoetis from $175.00 to $184.00 and gave the company a “neutral” rating in a research report on Wednesday, May 12th. Finally, Raymond James cut shares of Zoetis from an “outperform” rating to a “market perform” rating in a research report on Friday, July 16th. Seven investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $188.21.

NYSE ZTS traded up $1.14 on Thursday, hitting $199.18. 2,479 shares of the company were exchanged, compared to its average volume of 1,766,974. The stock has a market capitalization of $94.56 billion, a P/E ratio of 48.10, a PEG ratio of 3.46 and a beta of 0.65. Zoetis Inc. has a 12 month low of $141.41 and a 12 month high of $202.04. The stock’s fifty day moving average is $184.54. The company has a debt-to-equity ratio of 1.61, a quick ratio of 2.47 and a current ratio of 3.29.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 6th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.22. The business had revenue of $1.87 billion for the quarter, compared to analyst estimates of $1.73 billion. Zoetis had a net margin of 25.30% and a return on equity of 55.11%. Zoetis’s revenue was up 22.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.95 earnings per share. As a group, research analysts anticipate that Zoetis Inc. will post 4.5 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 1st. Investors of record on Wednesday, July 21st will be paid a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 0.50%. The ex-dividend date is Tuesday, July 20th. Zoetis’s dividend payout ratio is presently 25.97%.

Zoetis Company Profile

Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.

Featured Story: Google Finance Portfolio Tips and Tricks

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.